Cite
HARVARD Citation
Eng, C. et al. (n.d.). 418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors. Journal for immunotherapy of cancer. p. A444. [Online].